As of today (2024-04-24), Regulus Therapeutics's share price is $2.25. Regulus Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.05. Hence, Regulus Therapeutics's Price to Tangible Book Ratio of today is 2.15.
The historical rank and industry rank for Regulus Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
RGLS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.69 Med: 2.16 Max: 6
Current: 2.14
During the past 13 years, Regulus Therapeutics's highest Price to Tangible Book Ratio was 6.00. The lowest was 0.69. And the median was 2.16.
RGLS's Price-to-Tangible-Book is ranked better than 58.78% of 1218
companies
in the Biotechnology industry
Industry Median: 2.69
vs RGLS: 2.14
A closely related ratio is called PB Ratio. As of today, Regulus Therapeutics's share price is $2.25. Regulus Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.05. Hence, Regulus Therapeutics's P/B Ratio of today is 2.15.
Regulus Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Regulus Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regulus Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regulus Therapeutics Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Regulus Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Regulus Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Regulus Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Regulus Therapeutics (Regulus Therapeutics) Business Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGLS has been successfully added to your 